Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Berry Genomics

Biotech & Life Sciences · Dongcheng District, China · Founded 2010 · IPO 2017 Unicorn

Berry Genomics is a biotechnology company that provides prenatal genetic testing

Valuation
$481M
Market cap · May/2026
Revenue
$128M
Latest reported FY
EBITDA
$2.1M
Latest reported FY

Investors

2 investors on Berry Genomics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage
Series B+ 1 investor entered at this stage

Global footprint

Where Berry Genomics has talent and traffic

Workforce by country
3 countries with
team presence
🇨🇳 China68.8%
🇺🇸 United States22.9%
🇩🇪 Germany20%
3 countries shown
Web traffic by country
48K monthly visits
across markets
🇨🇳 China101%
Top 1 markets shown

Patent intelligence

$11M patent portfolio · 62 active families

Estimated portfolio value
$11M
2.3% of market cap · 243.5× smaller than top peer Illumina ($2.7B)
62 active patent families
Where Berry Genomics innovates BioinformaticsComputational biologyMolecular biologyLibraryMedicine

Where Berry Genomics concentrates vs peers

Each axis is a top-10 topic across Berry Genomics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Berry Genomics

An AI-synthesized read of the highest-engagement posts about Berry Genomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Berry Genomics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.